High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008–2020
Tidsskrift for Den norske legeforening · 2026
DOI: 10.4045/tidsskr.25.0498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tidsskrift for Den norske legeforening, 2026. Verfasst von Jakob Nordberg Nørgaard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Avdeling for blodsykdommer, Oslo myelomatosesenter, Oslo universitetssykehus, og, Institutt for klinisk medisin, Universitetet i Oslo. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Melphalan. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background and aim: High-dose melphalan and autologous haematopoietic stem-cell transplantation (ASCT) is effective against multiple myeloma. The type of treatment patients receive before and after ASCT may affect time to relapse and survival. The aim of this study was to compare the treatments administered before and after ASCT at the four hospitals offering ASCT in Norway during the period 2008-2020. Material and method: All patients who received ASCT as first-line treatment for multiple myeloma in Norway in the period 1 January 2008-31 December 2020 were included in the study. Data on demographics, disease and treatment were recorded. Patients were followed until disease progression, death or study completion.
Results
Patients who received ASCT at St Olav's University Hospital received almost exclusively bortezomib-cyclophosphamide-dexamethasone as induction therapy, while bortezomib-lenalidomide-dexamethasone dominated at the three other hospitals after 2017. Maintenance therapy was given to 27 % of patients receiving ASCT in Oslo, compared with 2-16 % at the other centres. Median progression-free survival ranged from 29 to 38 months, and median overall survival ranged from 102 to 120 months across the centres.
Interpretation
Significant variations were observed in the treatments administered before and after ASCT, especially after 2017. National guidelines allowed for multiple treatment options, which has resulted in heterogeneous treatment practices. These different treatment approaches may have contributed to differences in progression-free and overall survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Avdeling for blodsykdommer, Oslo myelomatosesenter, Oslo universitetssykehus, og, Institutt for klinisk medisin, Universitetet i Oslo.
- Avdeling for blodsykdommer, Oslo myelomatosesenter, Oslo universitetssykehus, og, Avdeling for blod- og kreftsykdommer, Stavanger universitetssjukehus.
- Institutt for klinisk og molekylær medisin, NTNU, og, Avdeling for blodsykdommer, St. Olavs hospital.
- Seksjon for blodsykdommer, Universitetssykehuset i Nord-Norge, og, Institutt for klinisk medisin, Universitetet i Tromsø.
- Medisinsk klinikk, Haukeland universitetssjukehus, og, Avdeling for blodsykdommer, Oslo universitetssykehus.
- Avdeling for blodsykdommer, Oslo myelomatosesenter, Oslo universitetssykehus.
Zitieren
APA
Nørgaard, J. N., Moore, K. L. F., Slørdahl, T. S., Vik, A., Tvedt, T. H. A., Monsen, H. B., & Schjesvold, F. (2026). High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008–2020. Tidsskrift for Den norske legeforening. https://doi.org/10.4045/tidsskr.25.0498
Vancouver
Nørgaard JN, Moore KLF, Slørdahl TS, Vik A, Tvedt THA, Monsen HB, et al. High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008–2020. Tidsskrift for Den norske legeforening. 2026. doi:10.4045/tidsskr.25.0498
BibTeX
@article{Nrgaard2026,
author = {Nørgaard, Jakob Nordberg and Moore, Kari Lenita Falck and Slørdahl, Tobias S and Vik, Anders and Tvedt, Tor Henrik Anderson and Monsen, Hedda Berg and Schjesvold, Fredrik},
title = {High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008–2020},
journal = {Tidsskrift for Den norske legeforening},
year = {2026},
doi = {10.4045/tidsskr.25.0498}
}
EUVIMED